-
Merck's Hepatitis C Drug Increases Anemia Risk, FDA Staff Says -Bloomberg (MRK)
Monday, April 25, 2011 - 8:09am | 23Bloomberg reports that Merck's (NYSE: MRK) Hepatitis C drug increases anemia risk, FDA staff says.
-
Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants (SNY)
Monday, April 25, 2011 - 8:03am | 71Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (NYSE: SNY), announced today that the U.S. Food and Drug Administration has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra®, to include a two-dose schedule for infants and children 9...
-
A Peek Into The Market Before The Trading Starts
Monday, April 25, 2011 - 7:36am | 361Pre-open movers US stock futures are higher this morning, as investors are awaiting new-home-sales data. Futures on the Dow Jones Industrial Average gained 31 points to 12,465.00 and futures on the S&P 500 stock index rose 3.60 points to 1,334.60. Nasdaq 100 futures surged 6 points to 2,381.50...
-
AstraZeneca and POZEN File Patent Infringement Lawsuit Against Dr. Reddy's
Monday, April 25, 2011 - 7:33am | 149POZEN Inc. (NASDAQ: POZN) today announced that it and AstraZeneca filed a lawsuit against Dr. Reddy's Laboratories in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO delayed-release tablets. In a Notice Letter sent to...
-
Mylan Launches First Generic Version of Femara Tablets
Monday, April 25, 2011 - 7:30am | 66Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Letrozole Tablets USP, 2.5 mg, under a previously announced settlement and license agreement with Novartis. Mylan was the first company to have filed a substantially complete ANDA containing a...
-
Top 4 Small-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest EPS Estimates (CHBT, MDCO, PTX, SCR)
Monday, April 25, 2011 - 1:22am | 150Below are the top small-cap drug manufacturers-other stocks on the NYSE, the NASDAQ and the AMEX in terms of earnings estimate for the next year. The earnings estimate for China-Biotics Inc (NASDAQ: CHBT) for the next year ending March, 2012 is $2.00 per share. CHBT's PEG ratio is 0.24. The...
-
Top 5 S&P 500 worst performers for the week – IRM, GILD, HOG, KEY and DV
Sunday, April 24, 2011 - 6:21am | 1285The S&P 500 underperformed the Dow Jones but was pretty much equal with the NASDAQ composite. The Dow Jones Industrial Index ended the trading week at 12506, which represents 1.33% from previous week, the NASDAQ on the other hand closed the week at 2820.16 representing 2.01% from its previous...
-
Obagi Medical Products Appoints Albert F. Hummel President (OMPI)
Thursday, April 21, 2011 - 4:11pm | 64Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that Albert F. Hummel has been appointed the Company's President and Chief Executive Officer. Mr. Hummel had been serving as interim President and Chief Executive Officer...
-
14 Biotech Buyout Ideas
Thursday, April 21, 2011 - 4:05pm | 127By Jack Fuller Biotech companies are hot right now, and we identified a few to keep an eye on. The following firms either have potential blockbusters in the pipeline or unique niches that make them attractive buyout candidates. One we like is Xenoport Inc. (XNPT). Xenoport faced concerns of going...
-
5 Likely Short Squeeze Opportunities
Thursday, April 21, 2011 - 4:03pm | 127By Jack Fuller Biotech companies are hot right now, and we identified a few to keep an eye on. The following firms either have potential blockbusters in the pipeline or unique niches that make them attractive buyout candidates. One we like is Xenoport Inc. (XNPT). Xenoport faced concerns of going...
-
14 Sustainable Dividend Payers to Consider
Thursday, April 21, 2011 - 4:01pm | 127By Jack Fuller Biotech companies are hot right now, and we identified a few to keep an eye on. The following firms either have potential blockbusters in the pipeline or unique niches that make them attractive buyout candidates. One we like is Xenoport Inc. (XNPT). Xenoport faced concerns of going...
-
6 Safe Yields Whether Q2 Is Foggy or Fair
Thursday, April 21, 2011 - 3:51pm | 121Investment Underground anticipates two scenarios for Q2 2011. Investors will head for the exits amid choppy markets, congressional debt grappling and QE2 curtailment, or investors will scoop up bargains paying dividends, often paying yields in excess of company bonds. Either way, these names should...
-
Some So-Called ‘Evil' Companies That Make Terrific Stocks
Thursday, April 21, 2011 - 3:48pm | 121Investment Underground anticipates two scenarios for Q2 2011. Investors will head for the exits amid choppy markets, congressional debt grappling and QE2 curtailment, or investors will scoop up bargains paying dividends, often paying yields in excess of company bonds. Either way, these names should...
-
Which of These 9 Grossly Overpaid CEOs Are Worth It?
Thursday, April 21, 2011 - 3:44pm | 121Investment Underground anticipates two scenarios for Q2 2011. Investors will head for the exits amid choppy markets, congressional debt grappling and QE2 curtailment, or investors will scoop up bargains paying dividends, often paying yields in excess of company bonds. Either way, these names should...
-
4 Undervalued Energy Stocks With Upside Potential
Thursday, April 21, 2011 - 3:41pm | 121Investment Underground anticipates two scenarios for Q2 2011. Investors will head for the exits amid choppy markets, congressional debt grappling and QE2 curtailment, or investors will scoop up bargains paying dividends, often paying yields in excess of company bonds. Either way, these names should...